Cover Image
市場調查報告書

全球體外毒性測試市場

Global In-Vitro Toxicology Testing Market

出版商 Mordor Intelligence LLP 商品編碼 358232
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
全球體外毒性測試市場 Global In-Vitro Toxicology Testing Market
出版日期: 2016年01月01日 內容資訊: 英文
簡介

全球體外毒性測試市場,從2014年的108億美元,預計至2020年末達到190億美元,預計2014年∼2020年以9.8%的年複合成長率成長。

本報告提供全球體外毒性測試市場調查分析,市場概要,推動市場要素、阻礙因素、機會,各市場區隔的市場分析,競爭情形,主要企業等系統性資訊。

第1章 簡介

第2章 主要成果

第3章 摘要整理

第4章 市場動態

  • 市場區隔
  • 推動市場要素
  • 阻礙市場要素

第5章 市場區隔

  • 各終端用戶
  • 各投藥法
  • 各技術
  • 各手法
  • 區分:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他

第6章 競爭情形

  • M&A
  • 契約、聯盟、夥伴關係
  • 新產品銷售
  • 新加入企業的建議

第7章 企業簡介

  • SIGMA-ALDRICH FINE CHEMICALS
    • 產業概要
    • 產品與服務
    • 財務
  • BIOVIA CORPORATION
    • 產業概要
    • 產品與服務
  • AGILENT TECHNOLOGIES
    • 產業概要
    • 產品與服務
    • 財務
  • CHARLES RIVER LABORATORIES
    • 產業概要
    • 產品與服務
    • 財務
  • COVANCE INCORPORATED
    • 產業概要
    • 產品與服務
    • 財務
  • GE HEALTHCARE
    • 產業概要
    • 產品與服務
    • 財務
  • THERMO FISHER SCIENTIFIC INC.
    • 產業概要
    • 產品與服務
    • 財務
  • QUEST DIAGNOSTICS INC.
    • 產業概要
    • 產品與服務
    • 財務
目錄

The global market for in-vitro toxicology testing was estimated at USD 10.8 billion in 2014. The market is projected to reach USD 19 billion by the end of 2020 at a CAGR of 9.8% during the forecast period 2014-2020.

Predictive in-vitro toxicology is the new cutting edge technology in biopharmaceutical research. It is considered one of the most significant steps in drug discovery. Predictive in-vitro toxicology is expected to improve the quality and quantity of drugs entering clinical studies. In addition, it improves the safety and efficiency of new compounds and allows compounds to be arranged early in the development process. Earlier and more lucrative identification of potential mechanisms that cause adverse drug reactions have significant potential for improving consequences in drug discovery.

Several industries require toxicity testing of their products. On the basis of end-users, the market is segmented into pharmaceutical industry, cosmetics and household products, chemicals industry and the food & beverages industry. Pharmaceutical industry has the largest market share. This is attributed to the adoption of in-vitro methods in the detection of toxic effects to curb drug development costs and initiatives such as AXLR8 program by the European Union.

Cosmetics is expected to be the fastest-growing industry in coming years with government support and amendment of European Union's Cosmetics Directive, which has set forth a ban on the use of animals in testing for any toxic effects of beauty products.

Rapid technological advances, ban on the use of animals for testing and advances in toxicity testing protocols are the major factors driving the growth of the in-vitro toxicology testing market. On the other hand, stringent regulatory framework and the inability of in-vitro models to detect certain anomalies are the major challenges faced by the market.

The market for in-vitro toxicology testing is segmented on basis of technology, methods and applications. Technology segment is sub-divided into High Throughput Screening (HTS), molecular imaging, cell culture, genomics, toxicogenomics, proteomics and metabolomics. In-vitro testing includes the following methods namely, cell-based assay, biochemical-based assay, in-silico-based and ex vivo-based methods. The application segment is further categorized into acute systemic toxicity, dermal toxicity, ocular toxicity pharmacokinetics & metabolism, organ-specific toxicity, reproductive/developmental toxicity and others.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Currently, Europe is the largest market for in-vitro toxicology testing, owing to the high prevalence of cosmetic product testing and government support, followed by North America. Asia-Pacific is the fastest-growing region. The emerging countries in the region such as China and India are expected to register moderately high growth rates compared to previous years because of low development costs and increase in investments.

Several players in this market are trying to expand their product portfolio in order to compete in the global market. Top companies are expanding their growth in this market by acquiring other companies while few others are using acquisition as a market entry strategy. The dominant players in this market are Agilent Technologies, Alere Inc., Bio-Rad, Sigma-Aldrich, Catalent Pharma Solutions, Charles River Laboratories, Covance, Cyprotex, Eurofins Scientific Inc., GE Healthcare, Thermo Fisher Scientific and Quest Diagnostics.

Table of Contents

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. RESEARCH APPROACH AND METHODOLOGY
    • 1.2.1. INTRODUCTION
    • 1.2.2. RESEARCH DESIGN

2. KEY DELIVERABLES

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1. MARKET SEGMENTATION
  • 4.2. MARKET DRIVERS
    • 4.2.1. CONSENSUS AGAINST USING ANIMALS IN TESTING PROCEDURES
    • 4.2.2. RAPID ADVANCES IN TECHNOLOGIES BOOSTING THE MARKET GROWTH
    • 4.2.3. ADVANCES IN TOXICITY TESTING PROTOCOLS
  • 4.3. MARKET RESTRAINTS
    • 4.2.1. THE INABILITY OF IN-VITRO MODELS TO DETECT CERTAIN ANOMALIES
    • 4.3.3. STRINGENT REGULATORY FRAMEWORK
    • 4.3.2. LIMITATIONS OF IN-VITRO TOXICOLOGY TESTING

5. MARKET SEGMENTATION

  • 5.1. BY END USER
    • 5.1.1. PHARMACEUTICALS
    • 5.1.2. FOOD INDUSTRY
    • 5.1.3. CHEMICALS INDUSTRY
    • 5.1.4. COSMETICS
    • 5.1.5. DIAGNOSTICS
    • 5.1.6. OTHERS
  • 5.2. BY MODE OF ADMINISTRATION
    • 5.2.1. DERMAL
    • 5.2.2. ORAL
    • 5.2.3. OCCULAR
    • 5.2.4. INHALATION
    • 5.2.5. INFUSION
    • 5.2.6. RECTAL ADMINISTRATION
    • 5.2.7. PARENTERAL ADMINISTRATION
    • 5.2.8. INTRA-ARTERIAL ADMINISTRATION
    • 5.2.9. INTRA-NASAL ADMINISTRATION
  • 5.3. BY TECHNOLOGY
    • 5.3.1. HIGH-THROUGH PUT SCREENING
    • 5.3.2. MOLECULAR IMAGING
    • 5.3.3. CELL CULTURE
    • 5.3.4. OMICS
      • 5.3.4.1. GENOMICS
      • 5.3.4.2. TOXICOGENOMICS
      • 5.3.4.3. PROTEOMICS
      • 5.3.4.4. METABOLOMICS
      • 5.3.4.5. OTHERS
  • 5.4. BY METHOD
    • 5.4.1. CELL-BASED ASSAY
    • 5.4.2. BIOCHEMICAL-BASED ASSAY
    • 5.4.3. IN-SILICO-BASED
    • 5.4.4. EX VIVO-BASED METHODS
    • 5.4.5. OTHERS
  • 5.5. SEGMENTATION BY GEOGRAPHY
    • 5.5.1. NORTH AMERICA
      • 5.5.1.1. USA
      • 5.5.1.2. CANADA
      • 5.5.1.3. MEXICO
    • 5.5.2. EUROPE
      • 5.5.2.1. UK
      • 5.5.2.2. GERMANY
      • 5.5.2.3. FRANCE
      • 5.5.2.4. SPAIN
      • 5.5.2.5. ITALY
      • 5.5.2.6. REST OF EUROPE
    • 5.5.3. ASIA-PACIFIC
      • 5.5.3.1. CHINA
      • 5.5.3.2. JAPAN
      • 5.5.3.3. INDIA
      • 5.5.3.4. SOUTH KOREA
      • 5.5.3.5. REST OF ASIA-PACIFIC
    • 5.5.4. REST OF THE WORLD

6. COMPETITIVE LANDSCAPE

  • 6.1. MERGERS & ACQUISITIONS
  • 6.2. AGREEMENTS, COLLABORATIONS & PARTNERSHIPS
  • 6.3. NEW PRODUCT LAUNCHES
  • 6.4. RECOMMENDATIONS TO NEW MARKET PLAYERS:

7. COMPANY PROFILES

  • 7.1. SIGMA-ALDRICH FINE CHEMICALS
    • 7.1.1. BUSINESS OVERVIEW:
    • 7.1.1. PRODUCTS & SERVICES:
    • 7.1.1. FINANCIALS:
  • 7.2. BIOVIA CORPORATION
    • 7.2.1. BUSINESS OVERVIEW:
    • 7.2.2. PRODUCTS & SERVICES
  • 7.3. AGILENT TECHNOLOGIES
    • 7.3.1. BUSINESS OVERVIEW:
    • 7.3.1. PRODUCTS & SERVICES:
    • 7.3.1. FINANCIALS:
  • 7.4. CHARLES RIVER LABORATORIES
    • 7.4.1. BUSINESS OVERVIEW
    • 7.4.2. PRODUCTS & SERVICES
    • 7.4.3. FINANCIALS
  • 7.5. COVANCE INCORPORATED
    • 7.5.1. BUSINESS OVERVIEW
    • 7.5.2. PRODUCTS & SERVICES
    • 7.5.3. FINANCIALS
  • 7.6. GE HEALTHCARE
    • 7.6.1. BUSINESS OVERVIEW
    • 7.6.2. PRODUCTS & SERVICES
    • 7.6.3. FINANCIALS
  • 7.7. THERMO FISHER SCIENTIFIC INC.
    • 7.7.1. BUSINESS OVERVIEW:
    • 7.7.2. PRODUCTS AND SERVICES:
    • 7.7.3. FINANCIALS:
  • 7.8. QUEST DIAGNOSTICS INC.
    • 7.8.1. BUSINESS OVERVIEW:
    • 7.8.2. PRODUCTS AND SERVICES:
    • 7.8.3. FINANCIALS:
Back to Top